menu search

Volitionrx highlights 2022 achievements as it advances to commercial operations

VolitionRx (NYSE-A:VNRX) has outlined its key achievements in 2022 as the organization transitions from a company solely focused on research and devel...

January 9, 2023, 6:46 am

Astrazeneca and daiichi sankyo's zauberkugel (magic bullet)

FDA and EU approved, the joint therapy Enhertu is set to become a blockbuster. The therapy targets HER-2 cance...

January 6, 2023, 10:11 am

Context therapeutics has 39.4m cash runway to advance pipeline programs; data update from oath phase 2 trial likely in mid-2023

Context Therapeutics (NASDAQ:CNTX) Inc has indicated in its corporate guidance for 2023 that with ample cash on hand, the company has the scope to a...

January 4, 2023, 9:41 am

Erasca to present at the 41st annual j.p. morgan healthcare conference

SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discoverin...

January 4, 2023, 8:00 am

Pyxis oncology reports inducement grants under nasdaq listing rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 23, 2022 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generati...

December 23, 2022, 9:45 pm

Agenus to present botensilimab data at late-breaking oral session at asco-gi

LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics ...

December 21, 2022, 8:30 am

Astrazeneca (azn) gets eu nod & chmp opinions for some drugs

The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver ...

December 20, 2022, 10:32 am

Guardant health drops 30% as cancer test disappoints

On Dec. 15, the highly anticipated results of Guardant Health Inc.'s ( GH , Financial) pivotal DNA blood test trial were revealed, and the results fel...

December 16, 2022, 6:17 pm

Guardant health (gh) stock sinks on disappointing blood test results

Guardant Health (NASDAQ: GH ) stock dropped nearly 33% after a test of its colon-cancer screening system disappointed investors. The company's Shield ...

December 16, 2022, 9:57 am

Agenus: advancement of botensilimab could create a great pivot point

Focus still remains on advancing balstilimab, but instead of just using it alone as a monotherapy against advanced ...

December 13, 2022, 5:57 am

Bellicum announces presentation by unc at ash 2022 on potential abrogation of ic9 car t-cell toxicities with rimiducid

HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunot...

December 11, 2022, 3:00 pm

Adaptive biotechnologies highlights new data showcasing the clinical utility of clonoseq® mrd testing in patients with blood cancers at the 64th ash annual meeting

Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-making More than 3...

December 10, 2022, 3:00 pm

Erasca announces pricing of underwritten offering of common stock

SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discoveri...

December 9, 2022, 12:32 pm

Bionano genomics announces american society of hematology (ash) annual meeting presentations featuring ogm utility across blood cancer research applications

A scientific workshop will feature Dr. Rashmi Kanagal-Shamanna from the University of Texas MD Anderson Cancer Center delivering a presentation on the...

December 9, 2022, 1:24 am

Aim immunotech reports positive safety, tolerability, and biological activity data from phase 1 ampligen study

AIM ImmunoTech Inc (NYSE:AIM) has reported positive safety, tolerability, and biological activity data from a Phase 1 study involving the intranasal a...

December 8, 2022, 9:06 am

Viracta therapeutics announces preliminary dose-ranging data from the phase 1b/2 trial of nana-val in advanced epstein-barr virus-positive (ebv+) solid tumors at the esmo immuno-oncology congress

Data from first two dose levels of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma support continued dose escalation to d...

November 30, 2022, 11:10 pm

Context therapeutics finds lead clinical development candidate for cancer treatment in ctim-76

Context Therapeutics (NASDAQ:CNTX) Inc has designated CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to ta...

November 29, 2022, 10:52 am

Astrazeneca adds focus on personalised cancer cell therapy with us$320mln acquisition

AstraZeneca PLC (LSE:AZN) will spend up to US$320mln to strengthen its cancer business with an acquisition specialising in an innovative cell therapy ...

November 29, 2022, 3:35 am

cancersucks donates $50k to children’s health foundation at benefit concert in tulsa

During the concert to raise money for cancer research, cancersucks donated $50,000 to Oklahoma Children...

November 29, 2022, 12:14 am

Immunogen: elucidating ramifications of the elahere approval

ImmunoGen recently gained the accelerated approval of mirvetuximab (Elahere) for resistant ovarian cancers...

November 24, 2022, 3:15 am


Search within

Pages Search Results: